Evidence map›Paper›PMID 40487189›Full record

ArticleJAC-antimicrobial resistance2025

Antimicrobial resistance trends of methicillin-resistant

Torunn Gresdal Rønning, Hege Enger, Jan Egil Afset, Christina Gabrielsen Ås

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Unmasking Methicillin-resistantFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Torunn Gresdal RønningThe Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Hege EngerThe Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Jan Egil AfsetDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Christina Gabrielsen ÅsThe Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.ORCID https://orcid.org/0000-0002-9605-3283

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The purpose of this study was to analyse nationwide trends in antimicrobial susceptibility and molecular epidemiology of all MRSA strains in Norway over a 10-year period. Materials and methods: All cases of MRSA in Norway from 2008 to 2017 were included, limited to the first case per year per individual ( Results: Despite an increase in MRSA cases, antimicrobial resistance rates remained stable throughout the study period. The most common susceptibility profile of the MRSA strains was resistance to cefoxitin alone (41.4%), while co-resistance (58.6%) was observed most commonly for erythromycin (31.0%), tetracycline (25.3%) and ciprofloxacin/norfloxacin (21.6%). Notably, associations were identified between specific resistance patterns and clinical variables, including higher resistance rates among healthcare-associated MRSA, particularly in older adults and nursing home residents. Geographic associations were also observed, linking specific resistance profiles to strains acquired in North America, Africa and Asia. Conclusions: The findings highlight a complex landscape of MRSA resistance in a low-prevalence country, characterized by a diverse genotypic population and stable longitudinal trends in resistance rates. However, the prevalence of co-resistance to one or more antibiotics among Norwegian MRSA strains was high and increasing. This study thus underscores the importance of continuous surveillance and adherence to antimicrobial guidelines.

Identifiers

PMID40487189
PMCPMC12141746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.